Previous 10 | Next 10 |
PHILADELPHIA, Jan. 04, 2021 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, ...
Cabaletta Bio ([[CABA]] -1.9%) has dosed the first patient in DesCAARTes Phase 1 trial of DSG3-CAART for the treatment of mucosal-dominant pemphigus vulgaris ((mPV)), a rare autoimmune blistering disease that is characterized by the loss of adhesion between cells of the skin or mucous me...
First patient ever infused with a CAAR (chimeric autoantibody receptor) T cell therapy product candidate expands the potential clinical application of CAR T technology beyond cancer into autoimmune diseases PHILADELPHIA, Dec. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. ...
PHILADELPHIA, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger, ...
Cabaletta Bio ([[CABA]] +5.0%) reports lower than expected Q3 net loss of $0.36. Issues pipeline update including:The Company is actively recruiting in Phase 1 trial evaluating safety and tolerability of its lead program DSG3-CAART in relapsed/refractory mucosal pemphigus vulgaris (MPV-rare s...
Cabaletta Bio (CABA): Q3 GAAP EPS of -$0.36 beats by $0.08.Cash and cash equivalents and investments of $118.1M.Press Release For further details see: Cabaletta Bio EPS beats by $0.08
PHILADELPHIA, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced financial results for the...
The following slide deck was published by Cabaletta Bio, Inc. in conjunction with this event. For further details see: Cabaletta Bio (CABA) Investor Presentation - Slideshow
PHILADELPHIA, Sept. 25, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced that Steven Nichtberger,...
PHILADELPHIA, Sept. 08, 2020 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies for patients with B cell-mediated autoimmune diseases, today announced its participation in fir...
News, Short Squeeze, Breakout and More Instantly...
PHILADELPHIA, July 02, 2024 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that Steven Nichtb...
2024-06-20 09:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
– No CRS, ICANS, infections or serious adverse events observed in either of the first two patients through data cut-off of May 28, 2024 – – CABA-201 exhibited anticipated profile of CAR T cell expansion and contraction with complete B cell depletion observed in both...